2. Search Result
Search Result
Results for "

ATR inhibitor

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

2

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111451
    Tuvusertib

    M1774; ATR inhibitor 1

    		 ATM/ATR Cancer
    Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ .
    Tuvusertib
  • HY-136270
    Gartisertib
    2 Publications Verification

    VX-803; M4344; ATR inhibitor 2

    		 ATM/ATR Cancer
    Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity .
    Gartisertib
  • HY-139609
    Camonsertib

    RP-3500; ATR inhibitor 4

    		 ATM/ATR mTOR Cancer
    Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .
    Camonsertib
  • HY-149952
    ATR-IN-23

    		ATM/ATR Cancer
    ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers .
    ATR-IN-23
  • HY-N12840
    Logmalicid B

    		Others Metabolic Disease
    Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .
    Logmalicid B
  • HY-153462
    ATR-IN-24

    		ATM/ATR Cancer
    ATR-IN-24 (Compound 1) is a ATR inhibitor. ATR-IN-24 has anticancer activity .
    ATR-IN-24
  • HY-147566
    ATR-IN-14

    		ATM/ATR Cancer
    ATR-IN-14 (compound 1) is a potent ATR kinase inhibitor. ATR-IN-14 inhibits ATR signaling pathways downstream CHKI protein phosphorylation, with inhibition of 98.03% at 25 nM. ATR-IN-14 shows good anticancer activity in LoVo cells, with an IC50 of 64 nM .
    ATR-IN-14
  • HY-153400
    ATR-IN-22

    		ATM/ATR Cancer
    ATR-IN-22 (Compound 34) is an orally active ATR inhibitor. ATR-IN-22 inhibits MIAPaCa-2 proliferation (IC50 <1 μM). ATR-IN-22 shows anti-tumor activity in colon cancer .
    ATR-IN-22
  • HY-147565
    ATR-IN-13

    		ATM/ATR Cancer
    ATR-IN-13 (compound A9) is a potent ATR kinase inhibitor, with an IC50 of 2 nM. ATR-IN-13 can be used for ATR kinase mediated diseases research, such as proliferative diseases and cancer .
    ATR-IN-13
  • HY-153729
    ATR-IN-29

    		ATM/ATR Cancer
    ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC50 value of 1 nM. ATR-IN-29 shows antiproliferative activity .
    ATR-IN-29
  • HY-147190
    ATR-IN-19

    		ATM/ATR Cancer
    ATR-IN-19 (Compound 15 R-configure) is an ATR inhibitor .
    ATR-IN-19
  • HY-147568
    ATR-IN-16

    		ATM/ATR Cancer
    ATR-IN-16 (compound 46) is a potent ATR kinase inhibitor. ATR-IN-16 shows good anticancer activity in LoVo cells, with an IC50 of 410 nM .
    ATR-IN-16
  • HY-147569
    ATR-IN-17

    		ATM/ATR Cancer
    ATR-IN-17 (compound 88) is a potent ATR kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC50 of 1 nM .
    ATR-IN-17
  • HY-142671
    ATR-IN-5

    		ATM/ATR Cancer
    ATR-IN-5 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .
    ATR-IN-5
  • HY-153393
    ATR-IN-21

    		ATM/ATR Cancer
    ATR-IN-21 (compound 60) is a potent ATR inhibitor with an IC50 value of <1000 nM .
    ATR-IN-21
  • HY-142672
    ATR-IN-6

    		ATM/ATR Cancer
    ATR-IN-6 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .
    ATR-IN-6
  • HY-142924
    ATR-IN-8

    		ATM/ATR Cancer
    ATR-IN-8 is a potent inhibitor of ATR. ATR is a key enzyme in the homologous recombination repair pathway and belongs to the PIKK family. ATR-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021143821A1, compound 3) .
    ATR-IN-8
  • HY-147570
    ATR-IN-18

    		ATM/ATR Cancer
    ATR-IN-18 (compound 2) is an orally active and potent ATR kinase inhibitor, with an IC50 of 0.69 nM. ATR-IN-18 shows antiproliferative activity in LoVo cells, with an IC50 of 37.34 nM. ATR-IN-18 has anti-tumor activity .
    ATR-IN-18
  • HY-144436
    ATR-IN-12

    		ATM/ATR Cancer
    ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC50 value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent agent discovery targeting ATR kinase .
    ATR-IN-12
  • HY-144435
    ATR-IN-11

    		ATM/ATR Cancer
    ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent agent discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease .
    ATR-IN-11
  • HY-151915
    ATR-IN-20

    		ATM/ATR mTOR Cancer
    ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC50 of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC50 of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .
    ATR-IN-20
  • HY-147567
    ATR-IN-15

    		ATM/ATR DNA-PK PI3K Cancer
    ATR-IN-15 (compound 1) is an orally active and potent ATR kinase inhibitor, with an IC50 of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC50 values of 47, 663 and 5131 nM, respectively .
    ATR-IN-15
  • HY-161615
    PROTAC ATR degrader-2

    		Apoptosis PROTACs Cancer
    PROTAC ATR degrader-2 (Compound 8i) is a PROTAC degrader for ATR, through of . PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC50 of 22.9 and 34.5 nM. APROTAC ATR degrader-2 induces apoptosis, inhibits proliferations of AML cells. PROTAC ATR degrader-2 exhibits good pharmacokinetics charachers and antitumor efficacy against AML in mouse model. (Pink: ATR ligand (HY-161616); Blue:E3 ligase ligand Lenalidomide (HY-A0003); Black: linker)
    PROTAC ATR degrader-2
  • HY-144214
    ATR-IN-10

    		ATM/ATR Cancer
    ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC50 value of 2.978 μM.
    ATR-IN-10
  • HY-145312
    ATR-IN-4

    		ATM/ATR Cancer
    ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC50s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .
    ATR-IN-4
  • HY-145450
    ATR-IN-9

    		Others Cancer
    ATR-IN-9 is a potent inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR) extracted from patent WO2020087170A1, compound 59, has an IC50 of 10 nM .
    ATR-IN-9
  • HY-15520
    CGK733
    5 Publications Verification

    		 ATM/ATR Cancer
    CGK733 is a potent ATM/ATR inhibitor, used for the research of cancer.
    CGK733
  • HY-19323
    Ceralasertib
    30+ Cited Publications

    AZD6738

    		 ATM/ATR Cancer
    Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC50 of 1 nM.
    Ceralasertib
  • HY-13816
    NU6027

    		CDK ATM/ATR Cancer
    NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with Kis of 2.5 µM and 1.3 µM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .
    NU6027
  • HY-13902
    Berzosertib
    10+ Cited Publications

    VE-822; VX-970

    		 ATM/ATR Cancer
    Berzosertib (VE-822) is an ATR inhibitor with a Ki value of less than 0.2 nM. It also inhibits ATM with a Ki of 34 nM.
    Berzosertib
  • HY-15521
    ETP-46464
    2 Publications Verification

    		 mTOR ATM/ATR Cancer
    ETP-46464 is an effective mTOR and ATR inhibitor with IC50s of 0.6 and 14 nM, respectively.
    ETP-46464
  • HY-14731
    VE-821
    Maximum Cited Publications
    38 Publications Verification

    		 ATM/ATR Cancer
    VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM.
    VE-821
  • HY-15557
    AZ20
    5+ Cited Publications

    		 ATM/ATR Cancer
    AZ20 is a potent and selective inhibitor of ATR with an IC50 of 5 nM, and has 8-fold selectivity against mTOR (IC50=38 nM).
    AZ20
  • HY-157941
    ART0380

    		ATM/ATR Cancer
    ART0380 is a potent and selective ATR kinase inhibitor. ART0380 has selective antitumor activity that can be used for the research of Ataxia-Telangiectasia Mutated (ATM) aberrant cancers .
    ART0380
  • HY-101566A
    Elimusertib hydrochloride
    5+ Cited Publications

    BAY 1895344 hydrochloride

    		 ATM/ATR Cancer
    Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib hydrochloride has anti-tumor activity . Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas .
    Elimusertib hydrochloride
  • HY-101566
    Elimusertib
    5+ Cited Publications

    BAY 1895344

    		 ATM/ATR Cancer
    Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib has anti-tumor activity . Elimusertib can be used for the research of solid tumors and lymphomas .
    Elimusertib
  • HY-101566S
    Elimusertib-d3

    BAY 1895344-d3

    		 ATM/ATR Cancer
    Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .
    Elimusertib-d3
  • HY-12016
    KU-55933
    30+ Cited Publications

    		 ATM/ATR Autophagy Cancer
    KU-55933 is a potent ATM inhibitor with an IC50 and Ki of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
    KU-55933
  • HY-112198
    AZ31

    		ATM/ATR Cancer
    AZ31 is a a potent, highly selective, and orally active ATM inhibitor with an IC50 of <1.2 nM for ATM enzyme, and an IC50 of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .
    AZ31
  • HY-B0097
    Floxuridine
    3 Publications Verification

    5-Fluorouracil 2'-deoxyriboside

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis Infection Cancer
    Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .
    Floxuridine
  • HY-19323A
    (S)-Ceralasertib
    1 Publications Verification

    (S)-AZD6738

    		 ATM/ATR Cancer
    (S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC50 of 2.578 nM . (S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. (S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition .
    (S)-Ceralasertib
  • HY-161138
    WK369

    		BCL6 Apoptosis Cancer
    WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
    WK369
  • HY-N6954
    Garcinone C
    1 Publications Verification

    		 ATM/ATR STAT CDK Cancer
    Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner .
    Garcinone C

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: